What is the Impact Factor of Investigational New Drugs?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Investigational New Drugs is 3.40, ranking in quartile Q2 of Web of Science (SCIE).

Is Investigational New Drugs indexed in Web of Science or Scopus?

Yes, Investigational New Drugs is indexed in Web of Science (SCIE, Q2 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 0.816 (Q2) and an H-index of 104.

Who publishes Investigational New Drugs and what is the Article Processing Charge (APC)?

Investigational New Drugs is published by Springer US. The estimated Article Processing Charge (APC) is approximately $3,315 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Investigational New Drugs?

The official ISO-4 abbreviation of Investigational New Drugs is "INVEST. NEW DRUGS" with common acronym "drug". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q2Scopus Q2SCImago #6,711Hybrid

Investigational New Drugs

Acronym:drug

•

Abbreviation (ISO):INVEST. NEW DRUGS

•

Identifier (ISSN):0167-6997(Print)/1573-0646(Online)

•

Publisher:Springer US

Official Website Submission Portal Compare

Clarivate IF (2026)

3.4↑ +0.7

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIEJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Investigational New Drugs

WoS Q2

Annual Impact Factor Metric

Current (2026):3.4

Scopus SJR & RankScopus Q2

0.816

#6,711

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

104

104 papers with at least that number of citations each

WoS: SCIE / JCRQ2

Self-Citation Rate3.3%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

156articles/year

33.73% Gold OA•94.64% Original Research

Aims & Scope

The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.

Topics Covered (Recognized by AI)

Medicine98.8%Biology96.6%Internal medicine93%Genetics91.4%Chemistry82.3%Surgery63.5%Cancer59.9%Chemotherapy53.2%Pharmacology53%Organic chemistry52.9%Pathology51.7%Biochemistry51.7%Toxicity39.4%Oncology38.5%Gastroenterology36.5%Cancer research36.1%Bioinformatics35.6%Immunology26.9%In vitro20.9%Clinical trial20.8%Gene20.7%

Primary Research Areas

Medicine Pharmacy

Official Website NLM PubMed Catalog Submission Portal SCImago Profile

0 calls

Special Issues

Calls for Papers

No active Calls for Papers found for this journal.

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

ONCOLOGY

Rank148/333

IndexSCIE

JCRSCIE2026

PHARMACOLOGY & PHARMACY

Rank143/356

IndexSCIE

JCISCIE2026

ONCOLOGY

Rank124/333

IndexSCIE

JCISCIE2026

PHARMACOLOGY & PHARMACY

Rank120/356

IndexSCIE

Category	Index	Rank	Quartile
ONCOLOGY	JCRSCIE	148/333	Q2
PHARMACOLOGY & PHARMACY	JCRSCIE	143/356	Q2
ONCOLOGY	JCISCIE	124/333	Q2
PHARMACOLOGY & PHARMACY	JCISCIE	120/356	Q2

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF3.4

Articles / Year41

Total Citations21

2025

IF2.7

Articles / Year101

Total Citations329

2024

IF3

Articles / Year74

Total Citations550

2023

IF3.4

Articles / Year91

Total Citations677

2022

IF3.651

Articles / Year124

Total Citations1,425

Year	Impact Factor	Articles / Year	Total Citations
2026	3.4	41	21
2025	2.7	101	329
2024	3	74	550
2023	3.4	91	677
2022	3.651	124	1,425
2021	3.85	165	2,925
2020	3.525	146	3,058
2019	2.663	177	4,570
2018	3.502	158	3,898
2017	—	136	4,400
2016	—	97	3,596
2015	—	117	3,922

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #6,711Scopus Q2SCImago Profile

Scopus Coverage:1983-2026

•

Scopus Broad Areas:MedicinePharmacology, Toxicology and Pharmaceutics

Scopus Citation Rank (SJR)Q2

0.816

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2

Citations / Doc (2 years)

2.76

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,315 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations875

3-Year Documents317

Citable Documents309

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate40.0%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

OncologyQ2

PharmacologyQ2

Pharmacology (medical)Q2

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 3.3%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

3区 (Zone 3)Medicine

Minor Category (Specific Field):

4区ONCOLOGY

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Investigational New Drugs (acronym: drug, abbr: INVEST. NEW DRUGS, ISSN: 0167-6997) is a peer-reviewed international scholarly journal in the field of Medicine, published by Springer US in United States since 1983. The periodical holds a Journal Impact Factor (JIF) of 3.40, ranking in quartile Q2 of Web of Science (SCIE), a Scopus SJR indicator of 0.816 (Q2), an H-index of 104.

The journal enforces rigorous peer evaluation with a publication frequency of Quarterly, an annual output of approximately 156 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,315 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.